Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Early research (Phase 1)Study completedNCT05411133
What this trial is testing

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Who this might be right for
Gastrointestinal CancerCholangiocarcinomaLiver Cancer+6 more
Arbele Pty Ltd 33
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Testing effectiveness (Phase 2)Ended earlyNCT04496674
What this trial is testing

Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

Who this might be right for
Lung Cancer Squamous Cell
German Cancer Research Center 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07095803
What this trial is testing

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Who this might be right for
Multiple Advanced Tumors After PD-1 Therapy Failure
Sheng Zhang 60
Early research (Phase 1)WithdrawnNCT02470559
What this trial is testing

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Who this might be right for
Malignant Ovarian Clear Cell TumorMalignant Ovarian Serous TumorRecurrent Fallopian Tube Carcinoma+14 more
Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)UnknownNCT04954456
What this trial is testing

Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

Who this might be right for
Advanced Malignant Tumor
Qilu Pharmaceutical Co., Ltd. 96
Not applicableNot Yet RecruitingNCT06155422
What this trial is testing

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Gang Chen (101199) 670
Early research (Phase 1)Study completedNCT05028556
What this trial is testing

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Metastatic or Locally Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd. 50
Early research (Phase 1)Active Not RecruitingNCT06369467
What this trial is testing

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Who this might be right for
Food Allergy
Regeneron Pharmaceuticals 6
Early research (Phase 1)Study completedNCT01723475
What this trial is testing

First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Bayer 47
Testing effectiveness (Phase 2)Looking for participantsNCT05958121
What this trial is testing

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics Biotechnologies GmbH 400
Testing effectiveness (Phase 2)Looking for participantsNCT07689851
What this trial is testing

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)Looking for participantsNCT05859750
What this trial is testing

AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Akeso 78
Testing effectiveness (Phase 2)Study completedNCT00464893
What this trial is testing

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Who this might be right for
Gastric CancerGastric Adenocarcinoma
Neovii Biotech 70
Large-scale testing (Phase 3)Looking for participantsNCT05730036
What this trial is testing

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 410
Early research (Phase 1)Looking for participantsNCT07270978
What this trial is testing

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
University of Virginia 23
Testing effectiveness (Phase 2)Looking for participantsNCT07423585
What this trial is testing

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Who this might be right for
Extensive Stage Lung Small Cell Carcinoma
Asrar Alahmadi 39
Testing effectiveness (Phase 2)Study completedNCT05792735
What this trial is testing

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Carcinoma
Shenzhen People's Hospital 27
Testing effectiveness (Phase 2)Study completedNCT04444167
What this trial is testing

Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Akeso 59
Next Page